Ocular Therapeutix™ Provides Business Update and Response to COVID-19 Global Pandemic
Ocular Therapeutix, Inc. (OCUL)
Last ocular therapeutix, inc. earnings: 3/12 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ocutx.com
Company Research
Source: Business Wire
BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced its response to the COVID-19 pandemic and related impact on Ocular Therapeutix’s business operations.“In the midst of the global COVID-19 pandemic, our first priority is for the safety and well-being of our employees, patients, clinical collaborators and customers,” said Antony Mattessich, President and Chief Executive Officer. “While we are doing everything in our power to respond appropriately to the current crisis, we are also preparing Ocular Therapeutix and our community of stakeholders to thrive in the future. The Company is well positioned despite the challenging economic conditions.Our clinical programs remain on track:The first two subjects in the higher-dose cohort of our OTX-TKI (axitinib intravitreal implant) Phase I clinical t
Show less
Read more
Impact Snapshot
Event Time:
OCUL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCUL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCUL alerts
High impacting Ocular Therapeutix, Inc. news events
Weekly update
A roundup of the hottest topics
OCUL
News
- Ocular Therapeutix, Inc. (NASDAQ: OCUL) had its price target lowered by analysts at HC Wainwright from $16.00 to $14.00. They now have a "buy" rating on the stock.MarketBeat
- Ocular Therapeutix, Inc. (NASDAQ: OCUL) had its price target lowered by analysts at JMP Securities from $24.00 to $22.00. They now have a "market outperform" rating on the stock.MarketBeat
- Ocular Therapeutix, Inc. (NASDAQ: OCUL) had its price target lowered by analysts at TD Cowen from $11.00 to $7.00. They now have a "hold" rating on the stock.MarketBeat
- Ocular Therapeutix™ Reports First Quarter 2024 Results [Yahoo! Finance]Yahoo! Finance
- Ocular Therapeutix™ Reports First Quarter 2024 ResultsGlobeNewswire
OCUL
Earnings
- 3/11/24 - Miss
OCUL
Sec Filings
- 5/23/24 - Form 144
- 5/23/24 - Form 144
- 5/7/24 - Form S-8
- OCUL's page on the SEC website